Semaglutide dosing and titration: the schedule, and what each dose step costs
0.25 mg to 2.4 mg: the label titration schedule, how long it takes, and the chart that shows why flat-rate pricing matters more with every dose escalation.
The Wegovy dose ladder
The label is specific for weight management: start 0.25 mg once weekly for 4 weeks, then 0.5 mg, then 1.0 mg, then 1.7 mg, each held about 4 weeks, reaching the 2.4 mg maintenance dose at week 17. The escalation exists to reduce gastrointestinal side effects; if a dose isn't tolerated, prescribers may hold or slow the increase. If a dose is missed by more than 5 days, guidance is to skip it and resume the schedule.
| Dose step | Duration | Earliest week | Note |
|---|---|---|---|
| 0.25 mg (start) | 4 weeks | Week 1 | Initiation; not maintenance |
| 0.5 mg | 4 weeks | Week 5 | Escalation |
| 1.0 mg | 4 weeks | Week 9 | Escalation |
| 1.7 mg | 4 weeks | Week 13 | Escalation |
| 2.4 mg (maintenance) | ongoing | Week 17 | Target maintenance dose |
How long titration realistically takes
The standard schedule reaches 2.4 mg at about 16 weeks, but many prescribers go slower for patients with side effects, and some patients maintain at a lower dose (e.g., 1.0 or 1.7 mg) if that's where they tolerate and respond well. The goal is the maximum tolerated effective dose, not necessarily the label maximum.
What each dose step costs — where pricing model matters
On a flat-rate plan the dose ladder is clinically driven; on dose-tiered plans, every rung costs money. At typical dose-tiered prices, reaching and maintaining 2.4 mg adds over $140/month versus the starting dose — and you spend most of your treatment life at maintenance.
Ozempic vs Wegovy dosing — and why it confuses pricing
Semaglutide's dosing story is genuinely confusing because the same molecule is sold under two brands with two different dose ceilings, and compounded programs borrow from both. Ozempic, approved for type 2 diabetes, titrates to a maximum of 2.0 mg weekly. Wegovy, approved for weight management, goes higher, to the 2.4 mg maintenance dose the STEP trials used. Compounded programs may target either endpoint, which means "semaglutide" on two price sheets can refer to meaningfully different maintenance doses. This is why comparing monthly prices without pinning down the dose is a trap: specify the maintenance dose you and your prescriber are targeting and ask for the price at that dose, not the starter price. On a flat-rate plan this distinction collapses — you pay the same regardless — which is part of flat-rate's underrated appeal. There's also a safety layer: compounded products often come as multi-dose vials with syringes, so the patient does more measuring, and the FDA has warned about dosing errors with compounded GLP-1s. A program with clear instructions and responsive support mitigates that risk.
Frequently asked questions
What is the semaglutide dosing schedule?
For weight management (Wegovy), start at 0.25 mg once weekly for 4 weeks, then escalate every 4 weeks — 0.5, 1.0, 1.7 mg — to the 2.4 mg maintenance dose at about week 17. The escalation reduces gastrointestinal side effects.
How long does it take to reach the full semaglutide dose?
The standard schedule reaches 2.4 mg at about 16 weeks. Many prescribers titrate more slowly based on tolerability, and some patients maintain at a lower dose if that's where they tolerate and respond best.
Does semaglutide dose affect monthly cost?
On flat-rate pricing: no — you pay the same at 0.25 mg and 2.4 mg. On dose-tiered pricing: yes — each escalation can add cost, so reaching 2.4 mg (where most patients maintain) can cost over $140/month more than the advertised starter price.
What is the maintenance dose of semaglutide?
For weight management, the target maintenance dose is 2.4 mg once weekly. Some patients maintain effectively at 1.0 or 1.7 mg if higher doses aren't tolerated. The right dose is a clinical decision made with a prescriber.
Three dosing questions that change the financial picture
The dose ladder is where pricing structure quietly determines your total cost, so three specific questions before enrollment surface the hidden math that a starter price conceals. First, ask what you will pay per month at the 2.4 mg maintenance dose, not at the starting dose. This is the number that matters, because you will spend the large majority of your treatment life at or near maintenance, and on a dose-tiered plan the maintenance price can be well over a hundred dollars a month higher than the advertised entry rate. Second, ask whether there is any extra charge to pause or slow your titration. Because side effects cluster at dose increases and some patients need to hold a dose longer, a plan that charges for flexibility penalizes exactly the patients who need it most; a good program builds slowing into the standard of care at no extra cost. Third, ask whether a dose-change consultation costs extra. Some programs charge a separate visit fee every time your dose is adjusted, which turns the normal titration schedule into a series of billable events. On a bundled flat-rate plan like NexLife, the answers to all three tend to be favorable — one price, no penalty to slow down, visits included — which is the practical reason flat-rate structures often produce the lowest real cost despite not always having the lowest headline number. Asking these three questions before you pay converts an opaque comparison into a clear one, and it costs nothing but a few minutes. Dosing itself always remains a decision for your prescriber.
Three dosing questions that change the financial picture
The dose ladder is where pricing structure quietly determines your total cost, so three specific questions before enrollment surface the hidden math that a starter price conceals. First, ask what you will pay per month at the 2.4 mg maintenance dose, not at the starting dose. This is the number that matters, because you will spend the large majority of your treatment life at or near maintenance, and on a dose-tiered plan the maintenance price can be well over a hundred dollars a month higher than the advertised entry rate. Second, ask whether there is any extra charge to pause or slow your titration. Because side effects cluster at dose increases and some patients need to hold a dose longer, a plan that charges for flexibility penalizes exactly the patients who need it most; a good program builds slowing into the standard of care at no extra cost. Third, ask whether a dose-change consultation costs extra. Some programs charge a separate visit fee every time your dose is adjusted, which turns the normal titration schedule into a series of billable events. On a bundled flat-rate plan like NexLife, the answers to all three tend to be favorable — one price, no penalty to slow down, visits included — which is the practical reason flat-rate structures often produce the lowest real cost despite not always having the lowest headline number. Asking these three questions before you pay converts an opaque comparison into a clear one, and it costs nothing but a few minutes. Dosing itself always remains a decision for your prescriber.
References
- Novo Nordisk. Wegovy (semaglutide) Prescribing Information — dosing and administration.
- Wilding JPH, et al. STEP 1 dose-escalation protocol. N Engl J Med. 2021.
- SemaglutideGLPOne July 2026 price report and trends page.
- U.S. FDA. Communications on dosing errors with compounded GLP-1 products.
Clinical figures from published trials and FDA labeling; pricing from provider-advertised rates checked July 2026 and subject to change. Educational, not medical or financial advice.